Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best healthcare stocks with the highest upside. Goldman Sachs initiated coverage of Soleno Therapeutics, Inc. (NASDAQ:SLNO) on October 7 with a Buy rating, assigning the stock a $125 price target.

The analyst told investors that Goldman Sachs expects Soleno Therapeutics, Inc.’s (NASDAQ:SLNO) Vykat XR to become a “foundational treatment” for Prader-Willi syndrome.

According to the firm, the drug should expand into a blockbuster franchise, and the recent pullback provides investors with an attractive entry point into Soleno Therapeutics, Inc.’s (NASDAQ:SLNO) shares.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics to treat rare diseases. The company focuses on the treatment of neurobehavioral and metabolic disorders. Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS).

While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.